About Us

 

About Us

We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In order to make this vision a reality, we brought together the most experienced management team, renowned scientists, industry leading investors and expert advisors, to form a collaborative ecosystem, united through the common goal of advancing the science of precision health.

Management Team

Kevin Hrusovsky
Kevin Hrusovsky
Executive Chairman and Chief Executive Officer

Kevin joined Quanterix in 2014 and serves as the Chief Executive Officer and Executive Chairman. While at Quanterix, Kevin has led the Company to achieve significant success and growth, recently securing a $46 million capital raise that elevated the Company’s valuation to ten times its revenue. With over 25 years of experience in the life sciences space, he has dedicated his career to transforming healthcare into personalized medicine, and has a proven track record of commercializing disruptive technologies. Kevin currently serves on the Board of Directors of several companies transforming the future of precision health, including Quanterix, BioreclamationIVT, Cell Signaling Technology, 908 Devices, SynapDx and Solect Energy, and is the founder of the Powering Precision Health Summit. He also serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. Prior to Quanterix, Kevin was President of PerkinElmer Life Sciences & Technology; CEO of Caliper Life Sciences; and CEO of Zymark Corporation. Earlier, he was President of FMC Pharmaceuticals and International Agricultural Products and held numerous management positions at DuPont. He is the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions in life sciences and personal medicine. Kevin holds a B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.

Ernest Orticerio
Vice President, Operations and Chief Financial Officer

Ernest joined Quanterix in early 2012 as Vice President, Finance and Administration and Chief Financial Officer to lead the company's accounting, finance, treasury, human resources and procurement functions. He is also responsible for developing the Quanterix Capital profile as the company transitions to commercial operations. Ernest has over 13 years of experience in the life sciences industry. Prior to joining Quanterix, he served in a number of accounting, finance and operations capacities with Millipore Corporation, most recently as Vice President, Finance. In addition to managing a number of critical organizational initiatives during his tenure with Millipore Corporation, Ernest served as Controller for Latin America, and Vice President, Global Customer Service and Global Operations Strategy Development. He started his career with McDonald's Corporation, holding a number of progressive accounting and finance positions supporting Operations, Marketing and Real Estate functions. He holds a B.S./B.A. from Bryant College.

David Duffy, Ph.D.
Vice President, Research and Chief Technology Officer

David joined Quanterix in 2007 and leads the team of scientists developing its single molecule detection technology. David is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis. He was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There David oversaw the development of a novel chemical technology that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, David was at Gamera Biosciences where he was a co-inventor of a centrifugal microfluidic that was acquired and commercialized by Tecan. He was a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. David was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge, and holds a Ph.D. in Physical Chemistry from the Department of Chemistry at the University of Cambridge.

Mark Roskey, Ph.D.
Vice President and General Manager of Applications and Reagents

Mark joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. He comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America's Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

Bruce Bal
Vice President of Operations, Service and Quality

Bruce joined Quanterix in 2016 as the Vice President of Operations, Service and Quality. He has over 20 years of operations experience in the life sciences industry. Most recently, Bruce served as Vice President of Operations at PerkinElmer after the acquisition of Caliper Life Sciences where he held the role of Senior Vice President of Operations. Bruce joined Caliper Life Sciences following the acquisition of Zymark, where he served as Vice President of R&D and Operations. He previously worked at FMC Corporation, as Director of Operations in the Biotechnology Division. He has also held a wide range of management positions in his 13 years at DuPont and was general manager of United States Pollution Control, Inc. Bruce holds a B.S. in Chemical Engineering from the University of Wisconsin and an M.B.A. from Loyola University, Louisiana.

Elisabeth Colunio
Vice President, Human Resources

Elisabeth joined Quanterix in 2016 to lead the Company’s human resources department. She brings over 15 years of experience in human resources, with a focus on benefits, employee relations, payroll, talent acquisition and management. Elisabeth joins Quanterix from Alkermes, where she served as HR Business Partner, responsible for the Commerical Organization. Prior to Alkermes, Elisabeth was the HR Director for Caliper Life Sciences  focusing on the Global Commercial Team. Elisabeth holds a BA from Simmons College.

Board of Directors

Kevin Hrusovsky
Kevin Hrusovsky
Executive Chairman and Chief Executive Officer, Quanterix

With over 25 years of experience in the life sciences industry, Kevin has dedicated his career to transforming the practices of medicine and health. As the founder of the Powering Precision Health Summit, Kevin spearheaded the creation of an executive think tank of researchers, scientists, physicians and innovators to highlight the latest research on new biomarkers that are transforming healthcare into personalized medicine. With a proven track record for commercializing disruptive technologies, Kevin joined Quanterix in 2014 and currently serves as the Chief Executive Officer and Executive Chairman. Kevin also serves on the Board of Directors of several companies shaping the future of precision health, including Quanterix, BioreclamationIVT, Cell Signaling Technology, 908 Devices, SynapDx and Solect Energy. He also serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. Prior to Quanterix, Kevin served as CEO of Caliper Life Sciences, turning the company into one of the fastest growing biotech businesses in the region, leading to a $600-million acquisition by PerkinElmer Life Sciences & Technology. Following the acquisition, Kevin served as President of PerkinElmer. Earlier, he was CEO of Zymark Corporation, President of FMC Pharmaceuticals and International Agricultural Products and held numerous management positions at DuPont. He formerly served on the boards of SeraCare, Caliper Life Sciences, Xenogen – XGEN and Alliant Medical Technology. He is the 2013 Entrepreneur of the Year from Ohio State University and holds an Honorary Doctorate degree from Framingham State University for contributions in life sciences and personal medicine. Kevin holds a B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.

Martin Madaus, Ph. D. Ph.
Chairman and Chief Executive Officer, Ortho Clinical Diagnostics

Martin brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Martin is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He holds a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, Germany.

Douglas Cole, M.D.
Douglas Cole, M.D.
Managing Partner, Flagship Ventures

Douglas is a General Partner at Flagship Ventures where he focuses on Life Science investments. Prior to Flagship, he served as Program Executive at Vertex Pharmaceuticals and as Medical Director at Cytotherapeutics. While at Flagship, he has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Receptos, and Agios Pharmaceuticals. He is a co-founder of Flagship portfolio company Ensemble Therapeutics, Permeon Biologics, and ModeRNA Therapeutics. In addition to Quanterix, he currently serves on the Board of Directors of Tetraphase Pharmaceuticals, Concert Pharmaceuticals, Agios, Selecta Biosciences, Avedro, Seventh Sense Biosystems, and Resolvyx Pharmaceuticals, and is an Observer on the Board of Directors of Alvine Pharmaceuticals. Douglas obtained post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at Massachusetts General Hospital. He holds an M.D. from the University of Pennsylvania School of Medicine and received an A.B. magna cum laude with High Distinction in English from Dartmouth College.

Keith L. Crandell
Keith L. Crandell
Co-Founder & Managing Director, ARCH Venture Partners

Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Keith has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp., Eichrom Industries, Nanophase Technologies, and Illinois Superconductor. He serves on the board of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace, and also as a director of the Illinois Venture Capital Association. Keith holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

John M. Connolly
John M. Connolly
Senior Advisor, Bain Capital Ventures

John joined Bain Capital Ventures in 2009 and currently serves as a Senior Advisor to the Bain Capital Ventures team, following several years as a Managing Director. John focuses on partnering with portfolio company CEOs and management teams to address strategic and operational issues associated with growth. John has a 30+ year proven track record of innovation, vision, and execution in creating successful businesses. As a multi-time CEO, John raised over $100 million and created over $1 billion in shareholder value in partnership with 12 financial sponsors. At Bain Capital Ventures, John has worked with over 25 portfolio companies to address strategic and operating issues, as well as to develop strategies and tactics to accelerate value. He has been a Chairman, Non-Executive Chairman, or Director on 15 boards. John holds a B.A. in Liberal Arts from St. Norbert College.

David Walt, Ph.D.
Founder, Director Tufts Institute for Innovation, Howard Hughes Medical Institute Professor at Tufts University

David is Robinson Professor of Chemistry at Tufts University and a Howard Hughes Medical Institute Professor. He is a member of the U.S. National Academy of Engineering, and a fellow of the American Association for the Advancement of Science and the American Institute for Medical and Biological Engineering. He serves on the Editorial Advisory Board of several journals including Analytical Chemistry, and Analytical and Bioanalytical Chemistry. David is the Scientific Founder and Chair of the Scientific Advisory Board at Quanterix, and a Director of Illumina. He has received numerous national and international awards recognizing his work including a National Science Foundation Special Creativity Award, The Biosensors and Bioelectronics Award, and the Samuel R. Scholes Award in Glass Science. He has published over 200 papers and holds over 45 patents. David holds a Ph.D. in Chemical Biology from SUNY, Stony Brook and a B.S. in Chemistry from the University of Michigan.

Paul Meister
Paul Meister
Co-founder, Liberty Lane Partners, LLC

Paul is co-founder of Liberty Lane Partners, LLC, a private investment company with diverse investments in healthcare and distribution-related industries. He is also Chairman and Chief Executive Officer of inVentiv Health. Paul previously served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively, as operations grew from two countries to 27, and sales expanded into 140 countries worldwide. He is a director of LKQ Corporation, Scientific Games Corporation, co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Paul holds an M.B.A. from Northwestern University.

Dennis Sandstedt
Dennis Sandstedt
Sr. Vice President, Corporate Business Development, bioMérieux

Dennis is the Vice President of the Business Development at bioMérieux, a world player in the field of in vitro diagnostics providing solutions for both clinical and industrial applications and holding leadership positions in microbiology. Dennis has worked at bioMérieux since 1989 with broad experience in Immunoassay, Microbiology, and Molecular diagnostics. Prior to his Business Development responsibility, Dennis has successively held positions in R&D Management, Marketing and Strategic Development, and Portfolio Management where he was involved in development and launch of the VIDAS® Immunoassay system and management of the VITEK® Microbiology franchise. Dennis holds a B.S. in Computer Science from Kansas University and an M.B.A. from Washington University in St. Louis.

Investors

ARCH Venture Partners
ARCH Venture Partners
ARCH Venture Partners

ARCH Venture Partners, one of the largest early stage technology venture firms in the U.S., invests in the development of seed and early stage advanced technology companies. ARCH enjoys special recognition as a leader in the commercialization of technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it cofounds with leading scientists and entrepreneurs, concentrating on bringing to market innovations in information technology, life sciences, and physical sciences. ARCH has approximately $1.5 billion under management through seven venture funds and has funded more than 150 new ventures over its 25-year history.

Bain Capital Ventures
Bain Capital Ventures

Bain Capital Ventures (BCV) partners with disruptive B2B startup founders to accelerate bringing their ideas to market. The firm’s investments range from seed to growth stage in enterprise software, infrastructure software and in industries being transformed by data. BCV has helped launch and commercialize more than 200 companies since 1984, including select prior investments in DocuSign, Kiva Systems, LinkedIn, Rapid7, SurveyMonkey and TellApart. BCV has approximately $3 billion in assets under management and offices in the Bay Area, New York City and Boston.

bioMérieux

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2014, revenues reached €1.698 billion with 88% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies.

Cormorant Asset Management

Cormorant Asset Management, LLC is a registered investment advisory firm located in Boston, Massachusetts. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity markets. The firm employs fundamental analysis to create its portfolios. It conducts in-house research to make its investments. The firm typically invests in companies in healthcare and life sciences sectors. Cormorant Asset Management, LLC was founded in 2013 and is based in Boston, Massachusetts.

Flagship Ventures

Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology.

Trinitas Capital

Trinitas is a credit-focused investment management firm with an emphasis on investing in senior secured bank loans. Trinitas' initial strategy for growth is focused on collateralized loan obligation (CLO) issuance and separate accounts. The Trinitas team of talented professionals has deep experience in investing in and managing bank loans, loan acquisition, loan origination, credit analysis, portfolio management, trading, collateralized loan obligation (CLO) investing, and CLO deal structuring and compliance.

Tufts University

Tufts University, located on campuses in Boston, Medford/Somerville and Grafton, Massachusetts, and in Talloires, France, is recognized among the premier research universities in the United States. Tufts enjoys a global reputation for academic excellence and for the preparation of students as leaders in a wide range of professions. A growing number of innovative teaching and research initiatives span all Tufts campuses, and collaboration among the faculty and students in the undergraduate, graduate and professional programs across the university's schools is widely encouraged.

Dr. David Walt

Dr. Walt is the Scientific Founder and Chair of the Scientific Advisory Board at Quanterix, and a Director of Illumina. He is a Robinson Professor of Chemistry at Tufts University and a Howard Hughes Medical Institute Professor. Dr. Walt is a member of the U.S. National Academy of Engineering, a fellow of the American Association for the Advancement of Science, and a fellow of the American Institute for Medical and Biological Engineering. Dr. Walt serves on the Editorial Advisory Board of several journals including Analytical Chemistry, Analytical and Bioanalytical Chemistry, Sensor Letters, and the Indian Journal of Biotechnology.

Hercules Capital, Inc.
Hercules Capital, Inc.

Hercules Capital, Inc. is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $6.1 billion to over 350 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC."

Partners

NFL
NFL

Throughout its history, the NFL has made the health and safety of its players a priority. At the youth level, the NFL's partnership with the Centers for Disease Control and Prevention and the league's support for USA Football, including the Heads Up Football initiative, helps parents, coaches, clinicians and athletes understand the signs and symptoms of head injuries. The league has successfully advocated for the passage of youth concussion laws in all 50 states. Through funding for medical studies, including a $30 million grant to the National Institutes of Health for medical research; collaboration with the military on research and recognizing and reporting potential head injuries; and the work of the NFL's medical committees, the NFL is committed to supporting and advancing science that will have an impact beyond football.

General Electric
General Electric

GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works.

Banyan Biomarkers

Banyan Biomarkers, Inc. is focused on developing a blood test that could be used by physicians and healthcare providers to rapidly and objectively detect the presence of mild and moderate TBI and improve the medical management of head injured patients. The Company’s test uses two brain specific protein biomarkers (Banyan UCH-L1™ and Banyan GFAP™) that rapidly appear in the blood after a brain injury. The development of this blood based TBI test is being supported by significant funding from the United States Department of Defense.

ImmunArray

Co-located in Rehovot, Israel and Richmond, Va., ImmunArray is a privately funded molecular diagnostics company dedicated to the development of novel blood-based tests that support the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company, which has introduced its first commercial tests, is currently conducting research in collaboration with leading clinicians and medical centers in the U.S. and Israel. The company was a grant recipient of the GE-NFL Head Health Challenge as well as secured additional corporate research funding to conduct research into the use of biomarkers to identify traumatic brain injury.

OriGene Technologies, Inc.
OriGene Technologies, Inc.

OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support academic, diagnostic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 12,000 purified human proteins produced from mammalian (HEK293) cells, over 50,000 high quality primary antibodies including TrueMAB™ mouse monoclonal antibodies and polyclonal antibodies made against full-length proteins for the conservation of native epitopes, validated “mono-specific” monoclonal antibodies called UltraMAB® which offer a unique solution to the critical issue of antibody specificity, >140,000 highly validated human tissues, and protein microarray products and services.

QuintilesIMS
QuintilesIMS

QuintilesIMS (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

Frontage Labs

Frontage Labs is a contract research organization who helps pharmaceutical and biotech companies bring promising drug candidates to market. We specialize in early phase drug development, providing bioanalytical labs, discovery stage and preclinical drug metabolism and pharmacokinetics, Phase I/IIa clinical studies and product development support. Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development and commercial launch in global markets.

Myriad RBM, Inc.
Myriad RBM, Inc.

Myriad RBM is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner. All services are performed in our CLIA certified laboratory. As a guide to drug development researchers, Myriad RBM also offers companion diagnostic, custom assay development, co-sponsored research programs, and innovative cell culture products and services. Myriad RBM is a wholly owned subsidiary of Myriad Genetics, Inc. (MYGN), a leading molecular diagnostic company based in Salt Lake City, Utah which develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests.

PBL Assay Science

PBL Assay Science works hand in hand with industry, academic, and government researchers to help solve difficult assay development and protein quantification problems. PBL Assay Science is a major provider of products, services, information, and know-how related to interferons, cytokines, antibodies, ELISAs, and assay solutions. The company employs state-of-the-art technology in conducting assay services and manufacturing world-class products for scientists around the globe. Known as a trusted source for high quality, high sensitivity ELISAs as well as interferon proteins and antibodies, PBL has expanded its assay services capabilities, including ultrasensitive cytokine detection services, and increased human cell-expressed cytokine and growth factor offerings.

RayBiotech, Inc.
RayBiotech, Inc.

RayBiotech is a leading Life Sciences company which provides proteins, antibodies and immunological kits as well as services used in scientific research, including proteomics, biotechnology and pharmaceutical development. RayBiotech has nearly 50 employees whose objectives are to provide excellent products and service worldwide to RayBiotech customers which include scientists in industry, academic and research institutes in 41 countries. RayBiotech is committed to accelerating customer success through innovation and leadership in the Life Sciences.

AssayGate, Inc.
AssayGate, Inc.

AssayGate, Inc. is dedicated to providing the most cost-effective testing services and immunoassay products with the widest selection of protein biomarkers and sample matrices. We value the opportunity to assist our customers in life science, biomedical and pharmaceutical research communities in accelerating the pace of their scientific discoveries and project progress. In addition to conventional bead-based multiplex assay services and ELISA kits for broad initial analyses of protein biomarker profiling, we offer ultra-sensitive immunoassay services and products established upon Simoa™ technology platform to detect low abundance targets difficult or impossible to measure with conventional methodologies.

KCAS Bioanalytical & Biomarker Services

KCAS Bioanalytical & Biomarker Services is a contract laboratory with 36+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 15 FDA inspections. Recently KCAS registered for Clinical Laboratory Improvement Amendments (CLIA) certification.

Platine Pharma Services
Platine Pharma Services

Based in France, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometric and ELISA technologies, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

Customers

Sanofi
Janssen
Merck
Pfizer
Biogen
Shire
Genentech
Lilly
NIH
Takeda
Washington University in St. Louis
University of Gothenburg

Request to Learn More